What is the Impact Factor of Expert Review of Anti-Infective Therapy?

According to the latest Clarivate Journal Citation Reports (JCR), the Journal Impact Factor of Expert Review of Anti-Infective Therapy is 4.60, ranking in quartile Q1 of Web of Science (SCIE).

Is Expert Review of Anti-Infective Therapy indexed in Web of Science or Scopus?

Yes, Expert Review of Anti-Infective Therapy is indexed in Web of Science (SCIE, Q1 quartile). Furthermore, in Scopus (SCImago), it holds an SJR rating of 1.024 (Q1) and an H-index of 110.

Who publishes Expert Review of Anti-Infective Therapy and what is the Article Processing Charge (APC)?

Expert Review of Anti-Infective Therapy is published by Taylor and Francis Ltd.. The estimated Article Processing Charge (APC) is approximately $3,413 USD, subject to institutional waivers and corresponding author affiliations.

What is the ISO-4 abbreviation and acronym of Expert Review of Anti-Infective Therapy?

The official ISO-4 abbreviation of Expert Review of Anti-Infective Therapy is "EXPERT REV ANTI-INFE" with common acronym "eri". This standardized title abbreviation is used in citation lists conforming to IEEE, APA, Harvard, or Vancouver styles.

WoS SCIE Q1Scopus Q1SCImago #4,728Top JournalReview JournalHybrid

Expert Review of Anti-Infective Therapy

Acronym:eri

•

Abbreviation (ISO):EXPERT REV ANTI-INFE

•

Identifier (ISSN):1478-7210(Print)/1744-8336(Online)

•

Publisher:Taylor and Francis Ltd.

Official Website Submission Portal Compare

Clarivate IF (2026)

4.6↑ +0.8

Journal Impact Factor

IF Trend↓

WoS Quartile

WoS SCIETop Tier

Clarivate WoS JCR

WoS Categories↓

JCR Release Date: 2026-06-17

Impact Factor Trend (2018–2026)

Clarivate IF trend for Expert Review of Anti-Infective Therapy

WoS Q1

Annual Impact Factor Metric

Current (2026):4.6

Scopus SJR & RankScopus Q1

1.024

#4,728

SCImago Journal Rank citation prestige weighting

Scopus Year: 2025

H-Index (2025)

110

110 papers with at least that number of citations each

WoS: SCIE / JCRTop Tier

Self-Citation Rate2.4%

Safe Level (< 15%)Warning Level (> 20%)

Self-citation below 15% indicates strong scholarly independence.

Volume & Open AccessHybrid

116articles/year

5.69% Gold OA•32.91% Original Research

Aims & Scope

Expert Review of Anti-Infective Therapy (ISSN 1478-7210) provides expert reviews on therapeutics and diagnostics in the treatment of infectious disease. Coverage includes antibiotics, drug resistance, drug therapy, infectious disease medicine, antibacterial, antimicrobial, antifungal and antiviral approaches, and diagnostic tests.

Topics Covered (Recognized by AI)

Medicine89.5%Biology88.6%Genetics71.1%Internal medicine62.3%Pathology53.7%Chemistry52.4%Immunology52%Biochemistry48.4%Microbiology42.4%Intensive care medicine41.5%Virology38.6%Antibiotics29.3%Geology29%Paleontology28%Psychology25.2%Bacteria24.4%Surgery24.1%Disease23.5%Virus22.3%Psychiatry21.3%

Primary Research Areas

Medicine Pharmacy

Official Website NLM PubMed Catalog Submission Portal SCImago Profile

0 calls

Special Issues

Calls for Papers

No active Calls for Papers found for this journal.

Expand

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI

JCRSCIE2026

INFECTIOUS DISEASES

Rank26/141

IndexSCIE

JCRSCIE2026

MICROBIOLOGY

Rank51/167

IndexSCIE

JCRSCIE2026

PHARMACOLOGY & PHARMACY

Rank88/356

IndexSCIE

JCISCIE2026

INFECTIOUS DISEASES

Rank65/141

IndexSCIE

JCISCIE2026

MICROBIOLOGY

Rank85/167

IndexSCIE

JCISCIE2026

PHARMACOLOGY & PHARMACY

Rank155/356

IndexSCIE

Category	Index	Rank	Quartile
INFECTIOUS DISEASES	JCRSCIE	26/141	Q1
MICROBIOLOGY	JCRSCIE	51/167	Q2
PHARMACOLOGY & PHARMACY	JCRSCIE	88/356	Q1
INFECTIOUS DISEASES	JCISCIE	65/141	Q2
MICROBIOLOGY	JCISCIE	85/167	Q3
PHARMACOLOGY & PHARMACY	JCISCIE	155/356	Q2

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year

2026Latest

IF4.6

Articles / Year105

Total Citations40

2025

IF3.8

Articles / Year105

Total Citations405

2024

IF4.2

Articles / Year111

Total Citations852

2023

IF5.7

Articles / Year111

Total Citations1,704

2022

IF5.854

Articles / Year82

Total Citations1,329

Year	Impact Factor	Articles / Year	Total Citations
2026	4.6	105	40
2025	3.8	105	405
2024	4.2	111	852
2023	5.7	111	1,704
2022	5.854	82	1,329
2021	5.091	122	3,047
2020	3.767	205	8,461
2019	3.09	98	4,538
2018	3.141	95	3,674
2017	—	86	3,671
2016	—	117	4,386
2015	—	138	6,080

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #4,728Scopus Q1SCImago Profile

Scopus Coverage:2003-2026

•

Scopus Broad Areas:Immunology and MicrobiologyMedicine

Scopus Citation Rank (SJR)Q1

1.024

Weighted prestige citation metric per document indexed in the Scopus database.

Quartile: Scopus Q1

Citations / Doc (2 years)

4.22

Average citations received per document published in the 2-year window.

2-Year Citation Window

Estimated Publication Fee (APC)

$3,413 USD

Estimated Article Processing Charge for Open Access publication.

Estimated cost / article

Scopus 3-Year Publication & Citation Window

3-Year Citations1,653

3-Year Documents375

Citable Documents338

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate41.0%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

Infectious DiseasesQ1

MicrobiologyQ2

Microbiology (medical)Q2

VirologyQ2

Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth

Self-citation: 2.4%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):

3区 (Zone 3)Medicine

Minor Category (Specific Field):

3区INFECTIOUS DISEASES

CAS Early Warning List History:

Updated annually: 2020 – 2024

2020

Not warned

2021

Not warned

2022

Not warned

2023

Not warned

2024

Not warned

Academic Intelligence Overview & Context

ImpaQ Analysis

Expert Review of Anti-Infective Therapy (acronym: eri, abbr: EXPERT REV ANTI-INFE, ISSN: 1478-7210) is a peer-reviewed international scholarly journal in the field of Medicine, published by Taylor and Francis Ltd. in England. The periodical holds a Journal Impact Factor (JIF) of 4.60, ranking in quartile Q1 of Web of Science (SCIE), a Scopus SJR indicator of 1.024 (Q1), an H-index of 110.

The journal enforces rigorous peer evaluation with a publication frequency of Monthly, an annual output of approximately 116 scientific articles. In terms of accessibility and author fees, it operates under the Hybrid model with an estimated APC of $3,413 USD. It serves as a benchmark publication platform for academics, researchers, and doctoral candidates seeking global research visibility.